PhaseBio Enters Worldwide License Agreement with MedImmune for a Reversal Agent for Ticagrelor
November 28, 2017 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
First-in-class and unique reversal agent for ticagrelor aims to address important unmet need for patients requiring antiplatelet therapyPotential for accelerated development timeline with Phase 1...
PhaseBio Announces Dosing of First Patient in an Exploratory Clinical Study of PB1046 for the Treatment of Pulmonary Arterial Hypertension
November 01, 2017 12:45 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced...
PhaseBio to Present Data on its Elastin-Like Polypeptide Biopolymer Technology Platform at the TIDES: Oligonucleotide & Peptide Therapeutics Conference
April 25, 2017 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., April 25, 2017 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases...
PhaseBio to Present at Needham & Company’s 16th Annual Healthcare Conference
March 29, 2017 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., March 29, 2017 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases...
PhaseBio Announces $14.7 Million in Convertible Notes to Advance Clinical Development of PB1046 in Orphan Cardiopulmonary Disorders
January 18, 2017 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Jan. 18, 2017 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with...
PhaseBio Announces Dosing of First Patients in Two-Part Phase 2a Study of PB1046 in Cardiopulmonary Disorders
August 08, 2016 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
First patients dosed in Part One, which is evaluating PB1046 in subjects with heart failurePart Two will examine PB1046 in subjects with cardiac dysfunction secondary to Duchenne muscular dystrophy;...
PhaseBio Announces Leadership Team Appointments
April 07, 2016 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
John S. Lee, M.D., Ph.D., named Chief Medical OfficerJohn P. Sharp, CPA, named Chief Financial Officer MALVERN, Pa., April 07, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a...
PhaseBio to Present at Needham & Company’s 15th Annual Healthcare Conference
April 04, 2016 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., April 04, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing...
PhaseBio Licenses Elastin-Like Polypeptide Biopolymer Technology to Duke University for Development of Small-Molecule Oncologic Drugs
March 24, 2016 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
Duke gains rights to ELP-small molecule conjugates in oncology PhaseBio retains rights to ELP technology in all other applications MALVERN, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- PhaseBio...
PhaseBio to Present at 23rd Annual Future Leaders in the Biotech Industry Conference
March 04, 2016 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., March 04, 2016 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing...